{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:21:48Z","timestamp":1746922908574},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.lungcan.2018.01.011","type":"journal-article","created":{"date-parts":[[2018,2,3]],"date-time":"2018-02-03T17:27:32Z","timestamp":1517678852000},"page":"90-96","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed\/platinum"],"prefix":"10.1016","volume":"118","author":[{"given":"Wei-Yu","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Chi","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Hsiu","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong-Jen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"30","key":"10.1016\/j.lungcan.2018.01.011_bib0005","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1200\/JCO.2015.62.1342","article-title":"Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update","volume":"33","author":"Masters","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 5","key":"10.1016\/j.lungcan.2018.01.011_bib0010","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","article-title":"Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up","volume":"27","author":"Novello","year":"2016","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2018.01.011_bib0015","doi-asserted-by":"crossref","first-page":"e37229","DOI":"10.1371\/journal.pone.0037229","article-title":"Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lungcan.2018.01.011_bib0020","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","article-title":"Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors","volume":"6","author":"Hanauske","year":"2001","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.lungcan.2018.01.011_bib0025","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/annonc\/mdq730","article-title":"Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population","volume":"22","author":"Tanaka","year":"2011","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2018.01.011_bib0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.lungcan.2011.01.024","article-title":"Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed","volume":"74","author":"Chen","year":"2011","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"1","key":"10.1016\/j.lungcan.2018.01.011_bib0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JTO.0b013e31827628ff","article-title":"Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed","volume":"8","author":"Christoph","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2018.01.011_bib0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.lungcan.2009.12.002","article-title":"The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer","volume":"69","author":"Chang","year":"2010","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"5","key":"10.1016\/j.lungcan.2018.01.011_bib0045","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00280-013-2299-2","article-title":"Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis","volume":"72","author":"Liu","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.lungcan.2018.01.011_bib0050","doi-asserted-by":"crossref","first-page":"e74284","DOI":"10.1371\/journal.pone.0074284","article-title":"Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.lungcan.2018.01.011_bib0055","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2008.19.1650","article-title":"Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer","volume":"27","author":"Smit","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2018.01.011_bib0060","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2009.23.6406","article-title":"Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426","volume":"28","author":"Adjei","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2018.01.011_bib0065","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1097\/JTO.0b013e3181ec18c4","article-title":"Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study","volume":"5","author":"Adjei","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2018.01.011_bib0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.lungcan.2012.07.009","article-title":"Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin","volume":"78","author":"Tiseo","year":"2012","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"10.1016\/j.lungcan.2018.01.011_bib0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2016.10.006","article-title":"A folylpoly-gamma-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer","volume":"102","author":"Fukuda","year":"2016","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"6","key":"10.1016\/j.lungcan.2018.01.011_bib0080","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3892\/etm.2012.730","article-title":"Correlation between thymidylate synthase gene polymorphisms and efficacy of pemetrexed in advanced non-small cell lung cancer","volume":"4","author":"Hu","year":"2012","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.lungcan.2018.01.011_bib0085","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: the role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.lungcan.2018.01.011_bib0090","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"New England J. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2018.01.011_bib0095","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"New England J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2018.01.011_bib0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1200\/JCO.2016.68.1841","article-title":"Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 trial (ET)","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2018.01.011_bib0105","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2003.11.019","article-title":"Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy","volume":"44","author":"Ryu","year":"2004","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"15","key":"10.1016\/j.lungcan.2018.01.011_bib0110","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1158\/1078-0432.CCR-04-0247","article-title":"Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy","volume":"10","author":"Zhou","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2018.01.011_bib0115","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1007\/s00432-014-1756-6","article-title":"Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients","volume":"140","author":"Krawczyk","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2018.01.011_bib0120","doi-asserted-by":"crossref","first-page":"e99843","DOI":"10.1371\/journal.pone.0099843","article-title":"Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer","volume":"9","author":"Du","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.lungcan.2018.01.011_bib0125","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/ijc.28892","article-title":"Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients","volume":"135","author":"Peng","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2018.01.011_bib0130","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.canlet.2014.07.023","article-title":"Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy","volume":"353","author":"Sullivan","year":"2014","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.lungcan.2018.01.011_bib0135","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/JTO.0b013e3181e7fe2a","article-title":"ERCC2\/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies","volume":"5","author":"Zhan","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2018.01.011_bib0140","doi-asserted-by":"crossref","first-page":"e79864","DOI":"10.1371\/journal.pone.0079864","article-title":"Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies","volume":"8","author":"Qin","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.lungcan.2018.01.011_bib0145","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/JTO.0b013e31824fe98c","article-title":"Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine\/platinum","volume":"7","author":"Liao","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2018.01.011_bib0150","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/annonc\/mdj135","article-title":"Polymorphisms in DNA repair genes modulate survival in cisplatin\/gemcitabine-treated non-small-cell lung cancer patients","volume":"17","author":"de las Penas","year":"2006","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2018.01.011_bib0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics (Oxford, England)"},{"key":"10.1016\/j.lungcan.2018.01.011_bib0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.mrrev.2016.11.003","article-title":"Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer","volume":"771","author":"Perez-Ramirez","year":"2017","journal-title":"Mutat. Res."},{"issue":"4","key":"10.1016\/j.lungcan.2018.01.011_bib0165","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1007\/s13277-013-1493-5","article-title":"The association between the ERCC1\/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis","volume":"35","author":"Yang","year":"2014","journal-title":"Tumour Biol."},{"issue":"5","key":"10.1016\/j.lungcan.2018.01.011_bib0170","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/COC.0b013e3181b9cedc","article-title":"Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer","volume":"33","author":"Li","year":"2010","journal-title":"Am. J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2018.01.011_bib0175","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.4238\/2014.October.31.14","article-title":"Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer","volume":"13","author":"Gao","year":"2014","journal-title":"Genet. Mol. Res.: GMR"},{"issue":"3","key":"10.1016\/j.lungcan.2018.01.011_bib0180","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.lungcan.2010.10.011","article-title":"No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis","volume":"72","author":"Yin","year":"2011","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"8","key":"10.1016\/j.lungcan.2018.01.011_bib0185","doi-asserted-by":"crossref","first-page":"e72251","DOI":"10.1371\/journal.pone.0072251","article-title":"Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis","volume":"8","author":"Qiu","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.lungcan.2018.01.011_bib0190","doi-asserted-by":"crossref","first-page":"e33200","DOI":"10.1371\/journal.pone.0033200","article-title":"Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients","volume":"7","author":"Wu","year":"2012","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.lungcan.2018.01.011_bib0195","first-page":"8654","article-title":"A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer","volume":"61","author":"Park","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2018.01.011_bib0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.dnarep.2014.03.009","article-title":"Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research","volume":"19","author":"Nagel","year":"2014","journal-title":"DNA Repair"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218300217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218300217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T10:25:59Z","timestamp":1535106359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218300217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":40,"alternative-id":["S0169500218300217"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed\/platinum","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}